Korean J Gastroenterol.  2021 May;77(5):220-226. 10.4166/kjg.2021.067.

Pediatric-onset Inflammatory Bowel Disease: What Are Different from Adult in the Treatment?

• Choi S
• Moon W

• KMID: 2516038
• DOI: http://doi.org/10.4166/kjg.2021.067

Abstract

Pediatric-onset inflammatory bowel disease differs from adults in its epidemiological and clinical characteristics and courses. Since it is diagnosed at a young age, the duration of the disease is relatively longer than in adults. Therefore, it is necessary to select drugs in consideration of long-term risks and benefits, and efforts such as therapeutic drug monitoring to maximize the treatment effects and minimize side effects are required. In addition, special considerations for treating pediatric-onset inflammatory bowel disease include attention to the effects of the disease on growth and development, nutrition, and psychosocial problems. In children, more aggressive treatment is needed to avoid missing therapeutic window of opportunity during periods of rapid growth and development. Finally, efforts should be made to ensure that the therapeutic goals of mucosal healing are achieved, the quality of life is restored, and the transition to adult therapy is well carried out.

Keyword

Pediatric Crohn’s disease; Pediatric ulcerative colitis; Therapeutics; Growth; Nutrition therapy

Reference

1. Barton JR, Gillon S, Ferguson A. 1989; Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983 marginal fall in ulcerative colitis, three-fold rise in Crohn's disease. Gut. 30:618–622. DOI: 10.1136/gut.30.5.618. PMID: 2786488. PMCID: PMC1434211.

2. Loftus EV Jr. 2004; Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 126:1504–1517. DOI: 10.1053/j.gastro.2004.01.063. PMID: 15168363.

3. Sýkora J, Pomahačová R, Kreslová M, Cvalínová D, Štych P, Schwarz J. 2018; Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol. 24:2741–2763. DOI: 10.3748/wjg.v24.i25.2741. PMID: 29991879. PMCID: PMC6034144.

4. Kwak MS, Cha JM, Lee HH, et al. 2019; Emerging trends of inflammatory bowel disease in South Korea: a nationwide population-based study. J Gastroenterol Hepatol. 34:1018–1026. DOI: 10.1111/jgh.14542. PMID: 30447025.

5. Hong SJ, Cho SM, Choe BH, et al. 2018; Characteristics and incidence trends for pediatric inflammatory bowel disease in Daegu-Kyungpook province in Korea: a multi-center study. J Korean Med Sci. 33:e132. DOI: 10.3346/jkms.2018.33.e132. PMID: 29713253. PMCID: PMC5920122.

6. Kim BJ, Song SM, Kim KM, et al. 2010; Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig Dis Sci. 55:1989–1995. DOI: 10.1007/s10620-009-0963-5. PMID: 19763825.

7. Levine A, Griffiths A, Markowitz J, et al. 2011; Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 17:1314–1321. DOI: 10.1002/ibd.21493. PMID: 21560194.

8. Markowitz J, Kugathasan S, Dubinsky M, et al. 2009; Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis. 15:714–719. DOI: 10.1002/ibd.20831. PMID: 19107777. PMCID: PMC2726983.

9. Gupta N, Bostrom AG, Kirschner BS, et al. 2008; Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am J Gastroenterol. 103:2092–2098. DOI: 10.1111/j.1572-0241.2008.02000.x. PMID: 18796101. PMCID: PMC3258513.

10. Jezernik G, Mičetić-Turk D, Potočnik U. 2020; Molecular genetic architecture of monogenic pediatric IBD differs from complex pediatric and adult IBD. J Pers Med. 10:243. DOI: 10.3390/jpm10040243. PMID: 33255894. PMCID: PMC7712254.

11. Moran CJ, Klein C, Muise AM, Snapper SB. 2015; Very early-onset inflammatory bowel disease: gaining insight through focused discovery. Inflamm Bowel Dis. 21:1166–1175. DOI: 10.1097/MIB.0000000000000329. PMID: 25895007. PMCID: PMC6165626.

12. Heyman MB, Kirschner BS, Gold BD, et al. 2005; Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 146:35–40. DOI: 10.1016/j.jpeds.2004.08.043. PMID: 15644819.

13. Benchimol EI, Mack DR, Nguyen GC, et al. 2014; Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. Gastroenterology. 147:803–e15. DOI: 10.1053/j.gastro.2014.06.023. PMID: 24951840.

14. Bequet E, Sarter H, Fumery M, et al. 2017; Incidence and phenotype at diagnosis of very-early-onset compared with later-onset paediatric inflammatory bowel disease: a population-based study [1988-2011]. J Crohns Colitis. 11:519–526.

15. Mamula P, Markowitz JE, Baldassano RN. 2003; Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol Clin North Am. 32:967–viii. DOI: 10.1016/S0889-8553(03)00046-3.

16. Kugathasan S, Judd RH, Hoffmann RG, et al. 2003; Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 143:525–531. DOI: 10.1067/S0022-3476(03)00444-X.

17. Newby EA, Croft NM, Green M, et al. 2008; Natural history of paediatric inflammatory bowel diseases over a 5-year follow-up: a retrospective review of data from the register of paediatric inflammatory bowel diseases. J Pediatr Gastroenterol Nutr. 46:539–545. DOI: 10.1097/MPG.0b013e3181596efd. PMID: 18493209.

18. Sauer CG, Kugathasan S. 2009; Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am. 38:611–628. DOI: 10.1016/j.gtc.2009.07.010. PMID: 19913205.

19. Van Limbergen J, Russell RK, Drummond HE, et al. 2008; Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 135:1114–1122. DOI: 10.1053/j.gastro.2008.06.081. PMID: 18725221.

20. Vernier-Massouille G, Balde M, Salleron J, et al. 2008; Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 135:1106–1113. DOI: 10.1053/j.gastro.2008.06.079. PMID: 18692056.

21. Sauer CG, Kugathasan S. 2010; Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Med Clin North Am. 94:35–52. DOI: 10.1016/j.mcna.2009.10.002. PMID: 19944797.

22. Meinzer U, Ideström M, Alberti C, et al. 2005; Ileal involvement is age dependent in pediatric Crohn's disease. Inflamm Bowel Dis. 11:639–644. DOI: 10.1097/01.MIB.0000165114.10687.bf. PMID: 15973117.

23. Levine A, Kugathasan S, Annese V, et al. 2007; Pediatric onset Crohn's colitis is characterized by genotype-dependent age-related susceptibility. Inflamm Bowel Dis. 13:1509–1515. DOI: 10.1002/ibd.20244. PMID: 17763471.

24. Ishige T. 2019; Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr. 8:16–22. DOI: 10.21037/tp.2018.12.04. PMID: 30881894. PMCID: PMC6382509.

25. Wilson DC, Thomas AG, Croft NM, et al. 2010; Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 50 Suppl 1:S14–S34. DOI: 10.1097/MPG.0b013e3181c92caa. PMID: 20081542.

26. Lee YJ, Oh SH, Kim KM. 2010; The principles of drug therapy of Crohn's disease in child and adolescent. Korean J Pediatr Gastroenterol Nutr. 13 Suppl 1:S59–S69. DOI: 10.5223/kjpgn.2010.13.Suppl1.S59.

27. Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. 2015; Infliximab "top-down" strategy is superior to "step-up" in maintaining long-term remission in the treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 60:737–743. DOI: 10.1097/MPG.0000000000000711. PMID: 25564801.

28. Choe YH. 2020; Precision medicine for pediatric inflammatory bowel disease: a perspective. Precis Future Med. 4:43–52. DOI: 10.23838/pfm.2020.00058.

29. Song SM, Kim Y, Oh SH, Kim KM. 2014; Nutritional status and growth in Korean children with Crohn's disease: a single-center study. Gut Liver. 8:500–507. DOI: 10.5009/gnl13183. PMID: 25228974. PMCID: PMC4164243.

30. Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. 2008; Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 14:839–849. DOI: 10.1002/ibd.20378. PMID: 18266237.

31. Brown AC, Rampertab SD, Mullin GE. 2011; Existing dietary guidelines for Crohn's disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol. 5:411–425. DOI: 10.1586/egh.11.29. PMID: 21651358.

32. Lee MN, Woo HI, Lee YM, et al. 2013; Successful azathioprine treatment with metabolite monitoring in a pediatric inflammatory bowel disease patient homozygous for TPMT*3C. Yonsei Med J. 54:1545–1549. DOI: 10.3349/ymj.2013.54.6.1545. PMID: 24142665. PMCID: PMC3809851.

33. Lee YJ, Hwang EH, Park JH, Shin JH, Kang B, Kim SY. 2016; NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn's disease. Eur J Gastroenterol Hepatol. 28:475–478. DOI: 10.1097/MEG.0000000000000564. PMID: 26735160.

34. Choi SY, Kang B, Lee JH, Choe YH. 2017; Clinical use of measuring trough levels and antibodies against infliximab in patients with pediatric inflammatory bowel disease. Gut Liver. 11:55–61. DOI: 10.5009/gnl16041. PMID: 27609485. PMCID: PMC5221861.

35. Choi SY, Kang B, Choe YH. 2019; Serum infliximab cutoff trough level values for maintaining hematological remission in pediatric inflammatory bowel disease. Gut Liver. 13:541–548. DOI: 10.5009/gnl18129. PMID: 30970435. PMCID: PMC6743797.

36. Choi SY, Choi YO, Choe YH, Kang B. 2020; Potential utility of therapeutic drug monitoring of adalimumab in predicting short-term mucosal healing and histologic remission in pediatric Crohn's disease patients. J Korean Med Sci. 35:e114. DOI: 10.3346/jkms.2020.35.e114. PMID: 32329259. PMCID: PMC7183843.

37. Assa A, Matar M, Turner D, et al. 2019; Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn's disease compared with reactive monitoring. Gastroenterology. 157:985–996.e2. DOI: 10.1053/j.gastro.2019.06.003. PMID: 31194979.

38. Mackner LM, Greenley RN, Szigethy E, Herzer M, Deer K, Hommel KA. 2013; Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 56:449–458. DOI: 10.1097/MPG.0b013e3182841263. PMID: 23287808. PMCID: PMC3609923.

39. Kim SC, Ferry GD. 2004; Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 126:1550–1560. DOI: 10.1053/j.gastro.2004.03.022. PMID: 15168366.

40. Miele E, Shamir R, Aloi M, et al. 2018; Nutrition in pediatric inflammatory bowel disease: a position paper on behalf of the porto inflammatory bowel disease group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 66:687–708. DOI: 10.1097/MPG.0000000000001896. PMID: 29570147.

41. Greenberg GR, Fleming CR, Jeejeebhoy KN, Rosenberg IH, Sales D, Tremaine WJ. 1988; Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut. 29:1309–1315. DOI: 10.1136/gut.29.10.1309. PMID: 3143625. PMCID: PMC1434018.

42. Forbes A, Escher J, Hébuterne X, et al. 2017; ESPEN guideline: clinical nutrition in inflammatory bowel disease. Clin Nutr. 36:321–347. DOI: 10.1016/j.clnu.2016.12.027. PMID: 28131521.

43. Meister D, Bode J, Shand A, Ghosh S. 2002; Anti-inflammatory effects of enteral diet components on Crohn's disease-affected tissues in vitro. Dig Liver Dis. 34:430–438. DOI: 10.1016/S1590-8658(02)80041-X.

44. Ruemmele FM, Veres G, Kolho KL, et al. 2014; Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 8:1179–1207. DOI: 10.1016/j.crohns.2014.04.005. PMID: 24909831.

45. Berni Canani R, Terrin G, Borrelli O, et al. 2006; Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis. 38:381–387. DOI: 10.1016/j.dld.2005.10.005. PMID: 16301010.

46. Borrelli O, Cordischi L, Cirulli M, et al. 2006; Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 4:744–753. DOI: 10.1016/j.cgh.2006.03.010. PMID: 16682258.

47. Kim S, Koh H. 2015; Nutritional aspect of pediatric inflammatory bowel disease: its clinical importance. Korean J Pediatr. 58:363–368. DOI: 10.3345/kjp.2015.58.10.363. PMID: 26576179. PMCID: PMC4644763.

48. Levine A, Wine E, Assa A, et al. 2019; Crohn's disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 157:440–450.e8. DOI: 10.1053/j.gastro.2019.04.021. PMID: 31170412.

49. Ruemmele FM, Turner D. 2014; Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. J Crohns Colitis. 8:1–4. DOI: 10.1016/j.crohns.2013.10.006. PMID: 24230969.

50. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. 2018; Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 67:257–291. DOI: 10.1097/MPG.0000000000002035. PMID: 30044357.

51. Aloi M, D'Arcangelo G, Pofi F, et al. 2013; Presenting features and disease course of pediatric ulcerative colitis. J Crohns Colitis. 7:e509–e515. DOI: 10.1016/j.crohns.2013.03.007. PMID: 23583691.

52. Malaty HM, Mehta S, Abraham B, Garnett EA, Ferry GD. 2013; The natural course of inflammatory bowel disease-indeterminate from childhood to adulthood: within a 25 year period. Clin Exp Gastroenterol. 6:115–121. DOI: 10.2147/CEG.S44700. PMID: 23901288. PMCID: PMC3726299.

53. Turner D, Levine A, Escher JC, et al. 2012; Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 55:340–361. DOI: 10.1097/MPG.0b013e3182662233. PMID: 22773060.

54. Turner D, Ruemmele FM, Orlanski-Meyer E, et al. 2018; Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 67:292–310. DOI: 10.1097/MPG.0000000000002036. PMID: 30044358.

55. Lee MN, Kang B, Choi SY, et al. 2015; Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine. Inflamm Bowel Dis. 21:1054–1062. DOI: 10.1097/MIB.0000000000000347. PMID: 25851563.

56. Yang SK, Hong M, Baek J, et al. 2014; A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 46:1017–1020. DOI: 10.1038/ng.3060. PMID: 25108385. PMCID: PMC4999337.

57. Hyams J, Crandall W, Kugathasan S, et al. 2007; Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 132:863–1166. DOI: 10.1053/j.gastro.2006.12.003. PMID: 17324398.

58. Hyams J, Walters TD, Crandall W, et al. 2011; Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 27:651–662. DOI: 10.1185/03007995.2010.547575. PMID: 21241207.

59. Vahabnezhad E, Rabizadeh S, Dubinsky MC. 2014; A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 20:606–613. DOI: 10.1097/MIB.0000000000000003. PMID: 24552827. PMCID: PMC5330671.

60. Chaparro M, Panes J, García V, et al. 2011; Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol. 45:113–118. DOI: 10.1097/MCG.0b013e3181ebaef9. PMID: 21242747.